CL2014002393A1 - Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos. - Google Patents

Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos.

Info

Publication number: CL2014002393A1
Authority: CL; Chile
Prior art keywords: pharmaceutical composition; binding molecules; therapeutic uses; ang2 binding; ang2
Prior art date: 2012-03-30

Application number

CL2014002393A

Other languages

English (en)

Spanish (es)

Inventor

Pascal Merchiers

Andreas Gschwind

Rene Georg Ott

Joachim Boucneau

Eric Borges

Erik Depla

Mari-Ange Buyse

Frederik Stevenaert

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-30

Filing date

2014-09-10

Publication date

2015-01-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002393(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-10 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-01-23 Publication of CL2014002393A1 publication Critical patent/CL2014002393A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Ophthalmology & Optometry (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CL2014002393A 2012-03-30 2014-09-10 Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos. CL2014002393A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12162615		2012-03-30

Publications (1)

Publication Number	Publication Date
CL2014002393A1 true CL2014002393A1 (es)	2015-01-23

Family

ID=48190468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002393A CL2014002393A1 (es)	2012-03-30	2014-09-10	Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos.

Country Status (27)

Country	Link
US (5)	US20130259859A1 (2)
EP (1)	EP2831111B1 (2)
JP (1)	JP5970734B2 (2)
KR (1)	KR102020255B1 (2)
CN (1)	CN104321344B (2)
AU (1)	AU2013241769B2 (2)
BR (1)	BR112014023415B1 (2)
CA (1)	CA2865464C (2)
CL (1)	CL2014002393A1 (2)
CY (1)	CY1122007T1 (2)
DK (1)	DK2831111T3 (2)
EA (1)	EA031182B1 (2)
ES (1)	ES2729165T3 (2)
HR (1)	HRP20190817T1 (2)
HU (1)	HUE044263T2 (2)
IL (1)	IL234234B (2)
IN (1)	IN2014DN06904A (2)
LT (1)	LT2831111T (2)
MX (1)	MX350248B (2)
NZ (1)	NZ628584A (2)
PH (1)	PH12014502179A1 (2)
PL (1)	PL2831111T3 (2)
PT (1)	PT2831111T (2)
RS (1)	RS58732B1 (2)
SI (1)	SI2831111T1 (2)
TR (1)	TR201908638T4 (2)
WO (1)	WO2013144266A1 (2)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
AU2015328411C1 (en)	2014-10-06	2022-03-03	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015331602A1 (en)	2014-10-17	2017-04-27	Amgen Inc.	Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
HK1250011A1 (zh) *	2015-03-31	2018-11-23	Sorriso Pharmaceuticals, Inc.	具有蛋白酶可切割接头的肽构建体
US10266589B2 (en) *	2015-07-29	2019-04-23	Allergan, Inc.	Heavy chain only antibodies to ANG-2
CA3040194A1 (en) *	2016-10-13	2018-04-19	Dana-Farber Cancer Institute, Inc.	Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
KR102143132B1 (ko) *	2016-12-26	2020-08-10	기초과학연구원	항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
CN109071656B (zh)	2017-01-05	2021-05-18	璟尚生物制药公司	检查点调节物拮抗剂
MX2019014199A (es) *	2017-06-02	2020-01-23	Boehringer Ingelheim Int	Tratamiento de combinacion antineoplasico.
CN108659130B (zh) *	2018-05-28	2021-09-10	长春力太生物技术有限公司	一种抗癌胚抗原纳米抗体及其应用
CN112739717B (zh)	2018-06-29	2025-02-11	璟尚生物制药公司	三特异性拮抗剂
CA3131250A1 (en) *	2019-02-25	2020-09-03	Pharmabcine Inc.	Anti-ang2 antibody and use thereof
US20220185875A1 (en) *	2019-03-18	2022-06-16	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific antibody specifically bound to vegf and ang2
US10851157B2 (en)	2019-07-01	2020-12-01	Gensun Biopharma, Inc.	Antagonists targeting the TGF-β pathway
JP2023516392A (ja) *	2020-03-03	2023-04-19	アプティテュードメディカルシステムズ、インコーポレイテッド	アプタマーおよびその使用
CN111875706B (zh) *	2020-07-16	2021-03-30	广州康盛生物科技股份有限公司	一种抗人IgE蛋白的单域抗体及其应用
US20240279324A1 (en)	2021-06-03	2024-08-22	Gensun Biopharma Inc.	Multispecific antagonists
JP2024534964A (ja) *	2021-09-10	2024-09-26	ソーター・バイオファーマ・プライベイト・リミテッド	抗ａｎｇ２抗体、その調製方法及び使用
WO2024065268A1 (zh)	2022-09-28	2024-04-04	科兴生物制药股份有限公司	能够识别ang-2的抗体或抗原结合片段和同时识别vegf和ang-2的双抗
CN115819592B (zh) *	2022-12-27	2026-04-24	上海医药集团生物治疗技术有限公司	靶向ror1的抗原结合蛋白
WO2025117641A2 (en) *	2023-12-01	2025-06-05	Tavotek Biotherapeutics (Hong Kong) Limited	ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF
WO2025137089A1 (en) *	2023-12-19	2025-06-26	Beam Therapeutics Inc.	Cd19-binding polypeptides, compositions comprising the same, and methods for use thereof
WO2026016001A1 (en) *	2024-07-15	2026-01-22	Quaerite Biopharm Research (Beijing) Co., Ltd.	Anti-ang2 monospecific and multispecific antibody constructs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU701578B2 (en)	1992-08-21	1999-02-04	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
US5643755A (en)	1994-10-07	1997-07-01	Regeneron Pharmaceuticals Inc.	Nucleic acid encoding tie-2 ligand
US5814464A (en)	1994-10-07	1998-09-29	Regeneron Pharma	Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
AU2002241922B2 (en)	2001-01-17	2007-10-25	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
DK1399484T3 (da)	2001-06-28	2010-11-08	Domantis Ltd	Dobbelt-specifik ligand og anvendelse af denne
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
US7205275B2 (en)	2001-10-11	2007-04-17	Amgen Inc.	Methods of treatment using specific binding agents of human angiopoietin-2
CA2505316C (en)	2002-11-08	2014-08-05	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041867A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
WO2005044858A1 (en)	2003-11-07	2005-05-19	Ablynx N.V.	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US20050284249A1 (en)	2004-06-29	2005-12-29	Arnone David F	Worm type gear mover assembly
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
BRPI0519596B1 (pt)	2004-12-21	2022-01-18	Astrazeneca Ab	Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
WO2006122787A1 (en)	2005-05-18	2006-11-23	Ablynx Nv	Serum albumin binding proteins
KR20090016762A (ko)	2006-06-06	2009-02-17	제넨테크, 인크.	혈관 발달을 조정하기 위한 조성물 및 방법
EP2057191A1 (en)	2006-08-18	2009-05-13	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010518839A (ja)	2007-02-21	2010-06-03	アブリンクスエン．ヴェー．	血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
CN101965362A (zh)	2008-03-05	2011-02-02	埃博灵克斯股份有限公司	新型抗原结合二聚体-复合物及其制备方法和应用
AU2009254501B2 (en) *	2008-06-05	2014-07-31	Ablynx N.V.	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US8858940B2 (en) *	2008-12-10	2014-10-14	Ablynx N.V.	Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9527925B2 (en) *	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) *	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2

2013
- 2013-03-27 TR TR2019/08638T patent/TR201908638T4/tr unknown
- 2013-03-27 MX MX2014011171A patent/MX350248B/es active IP Right Grant
- 2013-03-27 WO PCT/EP2013/056635 patent/WO2013144266A1/en not_active Ceased
- 2013-03-27 KR KR1020147028419A patent/KR102020255B1/ko active Active
- 2013-03-27 IN IN6904DEN2014 patent/IN2014DN06904A/en unknown
- 2013-03-27 SI SI201331449T patent/SI2831111T1/sl unknown
- 2013-03-27 CA CA2865464A patent/CA2865464C/en active Active
- 2013-03-27 ES ES13718796T patent/ES2729165T3/es active Active
- 2013-03-27 DK DK13718796.9T patent/DK2831111T3/en active
- 2013-03-27 EA EA201401065A patent/EA031182B1/ru not_active IP Right Cessation
- 2013-03-27 RS RS20190627A patent/RS58732B1/sr unknown
- 2013-03-27 BR BR112014023415-9A patent/BR112014023415B1/pt not_active IP Right Cessation
- 2013-03-27 LT LTEP13718796.9T patent/LT2831111T/lt unknown
- 2013-03-27 EP EP13718796.9A patent/EP2831111B1/en active Active
- 2013-03-27 AU AU2013241769A patent/AU2013241769B2/en not_active Ceased
- 2013-03-27 HR HRP20190817TT patent/HRP20190817T1/hr unknown
- 2013-03-27 NZ NZ628584A patent/NZ628584A/en not_active IP Right Cessation
- 2013-03-27 PT PT13718796T patent/PT2831111T/pt unknown
- 2013-03-27 CN CN201380026471.3A patent/CN104321344B/zh not_active Expired - Fee Related
- 2013-03-27 PL PL13718796T patent/PL2831111T3/pl unknown
- 2013-03-27 HU HUE13718796 patent/HUE044263T2/hu unknown
- 2013-03-27 JP JP2015502346A patent/JP5970734B2/ja not_active Expired - Fee Related
- 2013-03-28 US US13/852,402 patent/US20130259859A1/en not_active Abandoned
2014
- 2014-08-21 IL IL234234A patent/IL234234B/en active IP Right Grant
- 2014-09-10 CL CL2014002393A patent/CL2014002393A1/es unknown
- 2014-09-29 PH PH12014502179A patent/PH12014502179A1/en unknown
2016
- 2016-12-21 US US15/386,181 patent/US20170107281A1/en not_active Abandoned
2018
- 2018-07-02 US US16/025,067 patent/US20190135907A1/en not_active Abandoned
2019
- 2019-06-18 CY CY20191100625T patent/CY1122007T1/el unknown
2020
- 2020-03-13 US US16/817,700 patent/US20200207845A1/en not_active Abandoned
2023
- 2023-03-17 US US18/185,493 patent/US20230203146A1/en active Pending

Also Published As

Publication number	Publication date
KR102020255B1 (ko)	2019-09-10
HUE044263T2 (hu)	2019-10-28
HRP20190817T1 (hr)	2019-06-28
EP2831111A1 (en)	2015-02-04
AU2013241769A1 (en)	2014-08-28
DK2831111T3 (en)	2019-04-29
TR201908638T4 (tr)	2019-07-22
JP2015516805A (ja)	2015-06-18
CN104321344B (zh)	2017-11-21
PH12014502179B1 (en)	2014-12-10
CY1122007T1 (el)	2020-10-14
CN104321344A (zh)	2015-01-28
EA201401065A1 (ru)	2015-03-31
ES2729165T3 (es)	2019-10-30
PL2831111T3 (pl)	2019-09-30
AU2013241769B2 (en)	2017-05-11
PT2831111T (pt)	2019-05-31
IN2014DN06904A (2)	2015-05-15
US20230203146A1 (en)	2023-06-29
JP5970734B2 (ja)	2016-08-17
NZ628584A (en)	2016-04-29
MX2014011171A (es)	2015-03-06
US20130259859A1 (en)	2013-10-03
US20200207845A1 (en)	2020-07-02
WO2013144266A1 (en)	2013-10-03
IL234234B (en)	2020-06-30
KR20140146606A (ko)	2014-12-26
PH12014502179A1 (en)	2014-12-10
EA031182B1 (ru)	2018-11-30
BR112014023415B1 (pt)	2022-04-12
US20170107281A1 (en)	2017-04-20
CA2865464A1 (en)	2013-10-03
MX350248B (es)	2017-08-31
LT2831111T (lt)	2019-05-10
CA2865464C (en)	2022-07-12
SI2831111T1 (sl)	2019-06-28
RS58732B1 (sr)	2019-06-28
US20190135907A1 (en)	2019-05-09
BR112014023415A2 (pt)	2017-07-11
EP2831111B1 (en)	2019-03-20

Publication	Publication Date	Title
CL2014002393A1 (es)	2015-01-23	Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos.
CL2014003136A1 (es)	2015-02-27	Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2014002954A1 (es)	2015-02-06	Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
DK3608325T3 (da)	2022-08-22	Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
CO7061078A2 (es)	2014-09-19	Compuestos de enediino, conjugados de los mismos y sus usos y metodos
BR112015002790A2 (pt)	2017-08-08	anticorpos asgpr e usos dos mesmos.
DK3121164T3 (da)	2020-05-11	Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
BR112015001596A2 (pt)	2017-08-01	composição para o tratamento de hiperlipidemia que compreende oxintomodulina.
EP2896039A4 (en)	2016-05-25	IMPROVING THE PHONETIC DEBATE
DK3181128T3 (da)	2023-06-06	Farmaceutisk nilotinib-sammensætning
HUE046964T2 (hu)	2020-04-28	Kombinált gyógyászati készítmény
DK2818482T3 (da)	2019-07-15	Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da)	2019-07-29	Farmaceutisk sammensætning til behandling af cancer
DK2914965T3 (da)	2021-04-26	Aflukker til biologiske mikroobjekter
CO7051008A2 (es)	2014-09-10	Moléculas de unión específicas para her3 y usos de las mismas
DK2729151T3 (da)	2021-06-28	Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
CL2014002019A1 (es)	2015-01-16	Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CL2015000762A1 (es)	2015-08-07	Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf
BR112016018062A2 (pt)	2017-08-08	compostos terapêuticos, composição farmacêutica e usos
DK2914630T3 (da)	2021-04-26	Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft
DK3258938T3 (da)	2021-02-01	Phenothiazinanaloger som mitokondrie terapeutiske midler
DK2897594T3 (da)	2020-06-29	Farmaceutisk sammensætning
DK2809669T3 (da)	2017-05-01	Kondenserede pyrroldicarboxamider og deres anvendelse som farmaceutika
EP2813521A4 (en)	2016-03-02	CURABLE COMPOSITION AND APPLICATION THEREOF
CL2014002951A1 (es)	2014-12-26	(r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.